ethyl (S)-4-(3-chlorophenyl)-2-hydroxybutanoate | 1058856-49-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (S)-4-(3-chlorophenyl)-2-hydroxybutanoate
• CAS: 1058856-49-7
• 化学式: C₁₂H₁₅ClO₃
• 分子量: 242.702
• InChiKey: CUSXSVNKSAJLKA-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.53
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  (E)-ethyl 4-(3-chlorophenyl)-2-oxobut-3-enoate 在 盐酸 、 [NH2Me2]+[{RuCl[(S)-SunPhos]}2(μ-Cl3)] 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 70.0 ℃ 、1.4 MPa 条件下， 反应 12.0h， 生成 ethyl (S)-4-(3-chlorophenyl)-2-hydroxybutanoate
  参考文献：
  名称：

  Highly Enantioselective Sequential Hydrogenation of Ethyl 2-Oxo-4-arylbut-3-enoate to Ethyl 2-Hydroxy-4-arylbutyrate

  摘要：

  The hydrogenation of (E)-ethyl 2-oxo-4-arylbut-3-enoate with [NH2Me2](+)[{RuCl [(S)-SunPhos]}2(mu-Cl-3] gave ethyl 2-hydroxy-4-arylbutyrate with 94-96% ee. Further investigation has proved that the hydrogenation proceeded via a sequential hydrogenation of C = O and C = C bonds, which is sensitive to the reaction temperature. Hydrolysis of ethyl 2-hydroxy-4-phenylbutyrate (ee 93%) provided the 2-hydroxy-4-phenylbutyric acid with 81 % yield at 99% ee after a single recrystallization from 1, 2-dichloroethylene.

  DOI：

  10.1021/jo801140j

文献信息

• Direct Asymmetric Hydrogenation of 2-Oxo-4-arylbut-3-enoic Acids
  作者：Lvfeng Zhu、Qinghua Meng、Weizheng Fan、Xiaomin Xie、Zhaoguo Zhang

  DOI：10.1021/jo101084t

  日期：2010.9.3

  A challenging direct asymmetric hydrogenation of (E)-2-oxo-4-arylbut-3-enoic acids to give 2-hydroxy-4-arylbutanoic acids (85.4-91.8% ee) was achieved with a Ru catalyst based on SunPhos as the chiral ligand. Further investigation of the reaction revealed that partial isomerization of 2-hydroxy-4-arylbutenoic acids was involved in the hydrogenation process. Employing the reaction conditions to the hydrogenation of 2-oxo-4-phenylbutanoic acid resulted in better enantioselectivity (91.8% ee) and efficiency (TON = 2000, TOF = 200 h(-1)), which offers a useful method for the synthesis of a common intermediate for ACE inhibitors.